SCHEDULE 13G/A: Iroquois Capital Management Discloses 9.99% Stake in Petros Pharmaceuticals, Limited by Ownership Blockers

Iroquois Capital Management, LLC, along with its principals Richard Abbe and Kimberly Page, has disclosed a 9.99% beneficial ownership stake in Petros Pharmaceuticals, Inc., constrained by pre-existing beneficial ownership blockers on warrants and preferred shares.

Summary

• Iroquois Capital Management, LLC, Richard Abbe, and Kimberly Page (the "Reporting Persons") collectively reported beneficial ownership of 5,939,954 shares of Petros Pharmaceuticals, Inc. common stock as of March 31, 2025.
• This ownership represents 9.99% of the company's outstanding common stock, calculated based on 53,519,045 shares outstanding as of March 31, 2025, plus the 5,939,954 issuable shares.
• The reported stake includes shares issuable upon the exercise of warrants and conversion of preferred shares held by Iroquois Master Fund Ltd. and Iroquois Capital Investment Group LLC.
• The underlying securities include warrants exercisable for up to 20,341,760 shares for Iroquois Master Fund and 17,698,882 shares for ICIG, and preferred shares convertible into 1,612,172 shares for IMF and 352,641 shares for ICIG at a conversion price of $0.24.
• These warrants and preferred shares are subject to "Beneficial Ownership Blockers," which prevent the Reporting Persons from exercising or converting them if it would result in ownership exceeding 4.99% (for preferred shares and certain warrants) or 9.99% (for certain warrants) of the outstanding common stock.
• Due to these blockers, the Reporting Persons are currently prohibited from exercising certain warrants to exceed 5,939,954 shares or converting preferred shares/exercising certain warrants to exceed 2,810,862 shares.
• The reported 5,939,954 shares and 9.99% percentage already account for these beneficial ownership limitations.
• The Reporting Persons certify that the securities were not acquired for the purpose of changing or influencing control of the issuer, other than activities solely related to a nomination under Rule 14a-11.

Sentiment

Score: 5

Explanation: The document is a standard factual disclosure of beneficial ownership, providing no explicit positive or negative performance indicators or forward-looking statements that would influence sentiment.

Positives

• A significant institutional investor (Iroquois Capital Management) maintains a substantial stake, potentially indicating continued interest in Petros Pharmaceuticals.
• The filing provides transparency regarding the beneficial ownership structure and the specific limitations imposed by pre-existing agreements.

Negatives

• The existence of beneficial ownership blockers prevents the Reporting Persons from immediately converting or exercising a much larger pool of underlying securities (warrants and preferred shares), which could otherwise represent a significantly higher potential stake.

Risks

• The "Beneficial Ownership Blockers" limit the Reporting Persons' ability to fully realize their potential ownership from warrants and preferred shares, which could cap their upside if the stock price increases significantly.
• The large number of unexercised/unconverted warrants and preferred shares, held back by blockers, represents a potential source of future dilution if these blockers are removed or adjusted, or if the company issues more shares.

Future Outlook

NA

Industry Context

NA

Stakeholder Impact

• Shareholders: Provides transparency regarding a significant institutional investor's stake and the limitations on their potential full ownership, which could influence market perception and trading activity.

Key Dates

Keywords

Petros Pharmaceuticals, Iroquois Capital Management, Schedule 13G, beneficial ownership, common stock, warrants, preferred shares, ownership blockers, SEC filing, institutional investor, equity stake